Clinical trial NCT00034736: A Study to Compare the Efficacy and Safety of Levofloxacin in the Treatment of Children With Community-acquired Pneumonia in the Hospital or Outpatient Setting
Official title: A Multicenter, Randomized, Open-Label, Comparative Study to Compare the Efficacy and Safety of Levofloxacin and Standard of Care Therapy in the Treatment of Children With Community-Acquired Pneumonia in the Hospitalized or Outpatient Setting
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Pneumonia
Keywords: Pneumonia
Bacterial pneumonia
Community acquired pneumonia
Lung Inflammation
Quinolones
Levofloxacin
Ceftriaxone
Erythromycin
Clarithromycin
Lead sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Sponsor class: INDUSTRY
First posted: 2002-05-03
Enrollment: 691
Sex: ALL
Minimum age (years): 6
Maximum age (years): 16
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine the safety and efficacy of levofloxacin in the treatment of children with community acquired pneumonia.

Detailed description: This is a multicenter study to determine the efficacy of levofloxacin compared with the "standard of care" (antibiotic medication commonly used for the treatment of infection in question) in treating community acquired pneumonia in children aged 6 months to 16 years. The study consists of 4 phases: a 1-day screening period when patients will be tested for eligibility for the study; 10-day treatment, blood collection, and evaluation period; a post-treatment period beginning 1 to 3 days after the last dose of the study medication; and a post-study period 10 to 17 days after the last dose of study medication to assess whether the patient has been cured of pneumonia. Patients will be divided into 2 groups based upon age and then randomly assigned to receive up to 10 days of either levofloxacin or another antibiotic. The patients in Group 1 will be randomly assigned to levofloxacin or amoxicillin/clavulanate. The patients in Group 2 will be randomly assigned to receive levofloxacin or either ceftriaxone plus erythromycin lactobionate or clarithromycin. Safety evaluations will include laboratory tests, physical examinations, vital sign measurements, and recording of adverse events, including any adverse events affecting muscles or bones. Efficacy assessments include whether the patient was cured of pneumonia based on signs and symptoms of pneumonia reported before the start of the study. Additionally, at both the post-therapy and the post-study visits, responses will be evaluated by patients' signs and symptoms and by microscopic examination of the bacteria identified at the start of the study. The study hypothesis is that the treatment with levofloxacin will be effective in the treatment of children aged 6 months to 16 years with community acquired pneumonia and wil be well tolerated by the patients. Levofloxacin 10 mg/kg once or twice daily, amoxicillin/clavulanate 22.5 mg/kg twice daily, ceftriaxone 25 mg/kg twice daily plus erythromycin lactobionate 10 mg/kg every 6 hours or clarithromycin 7.5 mg/kg twice daily, either intravenously or by mouth for up to 10 days.

Eligibility criteria: Inclusion Criteria:

* Signs and symptoms of pneumonia including at least 2 of the following: fever, cough, chest pain, shortness of breath, physical examination showing lung tissue has become airless and of solid consistency, white blood cell count \>15,000/uL or \<5000/uL (normal range is approximately from 3800/uL to 9800/uL)
* Chest x-ray showing evidence of lung infection
* Production of sputum (not an absolute requirement for enrollment
* however, all reasonable attempts to obtain a sputum specimen should be made
* Parental consent to participate in the study

Exclusion Criteria:

* Patients who have used antibiotics that affect the whole body for more than 24 hours immediately before the start of the study
* Requirement of antibiotic therapy that affects the whole body, other than study drug(s)
* Suspected infection with a bacteria known to be resistant to any of the study drugs
* Signs and symptoms of infection with a bacteria that affects the central nervous system
* History of a previous sensitivity or serious adverse reaction to any antibiotic similar to those used in this study
* History of cystic fibrosis
* Abnormal kidney function, as determined by blood test (serum creatinine)
* History or presence of joint disease or disease of the tissues surrounding joints, or any other signs or symptoms in muscles or bones that may make it difficult to evaluate any future complaints concernng muscles or bones
* Hospitalization or residence in a long-term care facility for 14 or more days before the beginning of pneumonia symptoms
* Infection acquired in a hospital
* Poorly controlled seizure disorder or at significant risk for seizures
* Unstable psychiatric disorder
* Known or highly suspected to be infected tuberculosis
* Known HIV (human immunodeficiency virus) infection requiring treatment to prevent PCP (pneumocystis carinii pneumonia
* a type of pneumonia that mainly affects those with compromised immune systems)
* Persistent use of corticosteroids

Primary outcomes:
measure: Clinical cure rate (cured or not cured) at 10-17 days after the last dose of study medication.
Secondary outcomes:
measure: Clinical response rate (cure or improved response) at 1-3 days after the last dose. Rate of elimination of disease-causing bacteria at 1-3 and 10-17 days after the last dose. Safety evaluations monitored throughout the study.
Other outcomes:
Locations:
Study officials:
affiliation: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
name: Johnson & Johnson Pharmaceutical Research & Development, L.L. C. Clinical Trial
role: STUDY_DIRECTOR
References:
citation: Bradley JS, Arguedas A, Blumer JL, Saez-Llorens X, Melkote R, Noel GJ. Comparative study of levofloxacin in the treatment of children with community-acquired pneumonia. Pediatr Infect Dis J. 2007 Oct;26(10):868-78. doi: 10.1097/INF.0b013e3180cbd2c7.